Teachers Advisors LLC boosted its holdings in Flexion Therapeutics (NASDAQ:FLXN) by 28.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,719 shares of the specialty pharmaceutical company’s stock after purchasing an additional 14,374 shares during the quarter. Teachers Advisors LLC owned approximately 0.17% of Flexion Therapeutics worth $1,621,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of FLXN. SG Americas Securities LLC bought a new position in Flexion Therapeutics in the 3rd quarter worth approximately $135,000. Schwab Charles Investment Management Inc. boosted its stake in Flexion Therapeutics by 6.3% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 107,550 shares of the specialty pharmaceutical company’s stock worth $2,601,000 after purchasing an additional 6,336 shares during the period. Berson & Corrado Investment Advisors LLC bought a new position in Flexion Therapeutics in the 4th quarter worth approximately $324,000. Peregrine Capital Management LLC boosted its stake in Flexion Therapeutics by 11.4% in the 4th quarter. Peregrine Capital Management LLC now owns 662,875 shares of the specialty pharmaceutical company’s stock worth $16,598,000 after purchasing an additional 67,664 shares during the period. Finally, Legato Capital Management LLC bought a new position in Flexion Therapeutics in the 4th quarter worth approximately $447,000. Institutional investors and hedge funds own 94.46% of the company’s stock.
NASDAQ FLXN opened at $26.49 on Wednesday. The company has a quick ratio of 12.96, a current ratio of 13.02 and a debt-to-equity ratio of 0.58. The company has a market cap of $941.99, a PE ratio of -6.37 and a beta of 0.84. Flexion Therapeutics has a one year low of $16.51 and a one year high of $32.25.
Several research firms have weighed in on FLXN. Wells Fargo set a $39.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, April 3rd. BidaskClub upgraded Flexion Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, March 28th. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 target price (down from $37.00) on shares of Flexion Therapeutics in a research report on Friday, March 9th. ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 5th. Finally, Berenberg Bank started coverage on Flexion Therapeutics in a research report on Thursday, February 1st. They set a “buy” rating and a $42.00 target price for the company. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have given a buy rating to the stock. Flexion Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $99.00.
About Flexion Therapeutics
Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.
Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics (NASDAQ:FLXN).
Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.